London, July 7, 2026, 18:06 BST
- Haleon LON:HLN closed in London quoted at 367.00p/367.10p, gaining 1.92%. The FTSE 100 (INDEXFTSE:UKX) added 0.13%.
- Trading volume hit 37.5 million shares, up from 12.6 million on Monday. That’s almost triple the earlier total.
- Oral Health brought in nearly a third of revenue in Q1, up 8.3%. Respiratory Health, Pain Relief and Digestive Health all fell.
Haleon PLC LON:HLN ended the session quoted at 367.00p/367.10p, gaining 1.92% from Monday. FTSE 100 (INDEXFTSE:UKX) added 0.13%, according to Hargreaves Lansdown. Monday, Haleon dropped 1.59% to £3.59 as it trailed a 0.26% slide in the blue-chip index.
The move wasn’t just about price. On Monday, the stock dropped with volume at 12.6 million shares, well below the 50-day average of 25.4 million shown in Monday’s data. Volume jumped to 37.49 million shares during Tuesday’s rebound. The bounce had more trading behind it than the decline.
| Session | Haleon move | FTSE 100 move | Volume |
|---|---|---|---|
| Monday, July 6 | Shares fell 1.59% to £3.59 | Index slipped 0.26% to 10,651.77 | 12.6 mln shares changed hands |
| Tuesday, July 7 | Stock recovered 1.92% to 367.00p/367.10p | FTSE up 0.13% | Volume increased to 37.49 mln |
Monday’s volume came in about 50% under the 50-day average MarketWatch tracks. On Tuesday, volume jumped, about 48% above the same average. Shares remain about 12% off their February 18 high of roughly 416p.
Haleon hadn’t put out a new July 6-7 trading update on its RNS feed when checked. The last three posts were a director/PDMR notice on July 2, a total voting rights update on July 1, and a buyback announcement June 29. So, price and volume are the only new details, not anything from the company.
Haleon’s Q1 revenue came in at £2.857 billion, with organic growth at 2.2%. Oral Health, pushed by Sensodyne and parodontax, reported £932 million in sales, the same figure as the North America region. Meanwhile, Respiratory Health, Pain Relief and Digestive Health posted a combined £1.392 billion—nearly half of Q1 sales—but all three segments declined organically.
| Q1 2026 line | Revenue | Share of Q1 revenue | Organic revenue growth |
|---|---|---|---|
| Haleon total | £2.857 bln | 100% | +2.2% |
| Oral Health | £932 mln | 33% | +8.3% |
| Pain Relief | £654 mln | 23% | -0.3% |
| Respiratory Health | £499 mln | 17% | -3.4% |
| Digestive Health | £239 mln | 8% | -0.4% |
CEO Brian McNamara said “North America returning to growth” and “Oral Health again performing strongly” during the quarter. The company stuck to its 2026 outlook for 3% to 5% organic revenue growth and high-single-digit adjusted operating profit growth at constant currency. Haleon Corporate
Analyst sentiment is ahead of the stock’s latest move. LSEG data from Investors Chronicle listed 14 analysts with a median 12-month price target of 435p as of July 3. Ratings broke out to four buy, eight outperform, four hold, and two sell. That target is 18.5% above Tuesday’s 367.10p offer.
| Reference point | Pence | Gap vs Tuesday offer |
|---|---|---|
| Tuesday offer | 367.10p | — |
| 52-week high as of Monday | ~416p | +13% |
| Analyst median target | 435p | +18.5% |
Buybacks are still in the equity story, but they aren’t moving Haleon this July. The company has put £500 million toward 2026 buybacks and kicked off on-market repurchases in March. Q1 results showed about 36% finished by end of March. In its June 29 notice, Haleon said it bought 6.99 million shares for cancellation during the week of June 22.
Sales mix is the next watch point. Organic growth was 2.2% in Q1, below the full-year forecast, meaning there’s less room for weakness in Respiratory Health and Pain Relief if Oral Health slows.
